Home > Insider Trading > Filing (0001144204-14-027615)

Filing Details

Accession Number:: 0001144204-14-027615
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-05 18:01:50
Reporting Period:: 2014-05-01

Filing Date:: 2014-05-05
Accepted Time:: 2014-05-05 17:01:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1088856	Corcept Therapeutics Inc	CORT	Pharmaceutical Preparations (2834)	770487658

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1419701	L.p. Partners Venture Longitude	800 El Camino Real Suite 220 Menlo Park CA 94025	Yes	No	Yes	No
1430719	Longitude Capital Associates, L.p.	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No
1430720	Longitude Capital Partners, Llc	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No
1431159	Juliet Bakker Tammenoms	Longitude Capital Management Co., Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-05-01	160,343	$4.12	12,595,325	No	4	S	Direct
Common Stock	Disposition	2014-05-01	3,214	$4.12	174,691	No	4	S	Direct
Common Stock	Disposition	2014-05-02	84,744	$4.07	12,510,581	No	4	S	Direct
Common Stock	Disposition	2014-05-02	1,699	$4.07	172,992	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0700 to $4.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
Does not include warrants held by Longitude Venture Partners, L.P. ("LVP") to purchase 3,091,479 shares of common stock.
Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital") and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
Does not include warrants held by Longitude Capital Associates, L.P. ("LCA") to purchase 26,583 shares of common stock.
Reflects transactions and holdings of shares of common stock held of record by LCA. This report is jointly filed by LCA, Longitude Capital and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein.
Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0000 to $4.1100. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.